FDA Accepts Immunome’s NDA for Varegacestat in Desmoid Tumors, Setting Up an April 2027 Decision
2h agoen
Source
OncoDailyFDA Accepts Immunome’s NDA for Varegacestat in Desmoid Tumors, Setting Up an April 2027 Decisiononcodaily.comKey Takeaways The FDA has accepted Immunome’s New Drug Application (NDA) for varegacestat in adults with desmoid tumors, with a PDUFA target action date of April 28, 2027. The filing […]
You might also wanna read
Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference
Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre
avacta.com·13d ago
EMA begins phased review of daraxonrasib for metastatic pancreatic cancer treatment
The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, a medicine for metastatic pancreatic cancer. This acceler
ema.europa.eu·1d agoDaraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
nejm.org·1mo ago
New daily pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients
A new daily pill called daraxonrasib, which targets a gene behind pancreatic cancer, nearly doubled overall survival time for patients with
to.pbs.org·1mo agohttps://doi.org/10.1056/NEJMoa2517384
doi.org·1mo ago
New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'
Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the forma
sciencealert.com·29d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.